Theresa Winhusen1, Jeff Theobald1, David C Kaelber2,3,4, Daniel Lewis1. 1. Addiction Sciences Division, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA. 2. Department of Information Services, The MetroHealth System, Cleveland, OH, USA. 3. Departments of Internal Medicine, Pediatrics, and Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, USA. 4. The Center for Clinical Informatics Research and Education, The MetroHealth System, Cleveland, OH, USA.
Abstract
BACKGROUND AND AIMS: Screening for substance use disorder (SUD) in general medical settings may be particularly important in patients with comorbid health conditions exacerbated by SUD. This study evaluated whether SUD is associated with type 2 diabetes mellitus (T2DM) complications in patients with co-occurring T2DM and hypertension. DESIGN: Analysis of a limited data set obtained through IBM Watson Health Explorys, a platform integrating data from electronic health records. Matched controls were defined for each of five SUDs: tobacco use disorder (TUD), opioid use disorder (OUD), cocaine use disorder, cannabis use disorder (CUD) and alcohol use disorder (AUD) using Mahalanobis distance within propensity score calipers. SETTING: All patients were seen in the MetroHealth System (Cleveland, OH, USA) and had diagnosis codes for T2DM and hypertension. PARTICIPANTS: SUD group participants had a diagnosis of abuse/dependence for the substance of interest. Controls for each SUD group had no diagnosis code related to the SUD of interest and were selected to match the SUD patients on demographics, residential zip code median income and body mass index. Total sample sizes for each SUD-control comparison ranged from 1160 for CUD to 22 128 for TUD. MEASUREMENTS: Outcome was diagnosis (yes/no) of four T2DM complications (cerebrovascular accident, diabetic neuropathy, diabetic renal disease, myocardial infarction) and all-cause mortality. FINDINGS: Logistic regressions revealed that SUD was significantly associated with greater risk of cerebrovascular accident [TUD odds ratio (OR) = 1.79, OUD-OR = 1.94, cocaine use disorder OR = 2.67], diabetic neuropathy [TUD-adjusted OR (aOR) = 1.47, cocaine use disorder-aOR = 1.35, AUD-aOR = 1.27], diabetic renal disease (TUD-aOR = 1.25, OUD-OR = 1.34), myocardial infarction (TUD-OR = 1.96, OUD-OR = 2.01, cocaine use disorder-OR = 2.68, CUD-OR = 2.48, AUD-OR = 1.42) and mortality (TUD-OR = 1.15, cocaine use disorder-OR = 1.61, CUD-OR = 1.49, AUD-OR = 1.35). CONCLUSIONS: Among patients in Ohio USA with both type 2 diabetes mellitus (T2DM) and hypertension, those with substance use disorders appear to have greater risk for T2DM complications and all-cause mortality.
BACKGROUND AND AIMS: Screening for substance use disorder (SUD) in general medical settings may be particularly important in patients with comorbid health conditions exacerbated by SUD. This study evaluated whether SUD is associated with type 2 diabetes mellitus (T2DM) complications in patients with co-occurring T2DM and hypertension. DESIGN: Analysis of a limited data set obtained through IBM Watson Health Explorys, a platform integrating data from electronic health records. Matched controls were defined for each of five SUDs: tobacco use disorder (TUD), opioid use disorder (OUD), cocaine use disorder, cannabis use disorder (CUD) and alcohol use disorder (AUD) using Mahalanobis distance within propensity score calipers. SETTING: All patients were seen in the MetroHealth System (Cleveland, OH, USA) and had diagnosis codes for T2DM and hypertension. PARTICIPANTS: SUD group participants had a diagnosis of abuse/dependence for the substance of interest. Controls for each SUD group had no diagnosis code related to the SUD of interest and were selected to match the SUD patients on demographics, residential zip code median income and body mass index. Total sample sizes for each SUD-control comparison ranged from 1160 for CUD to 22 128 for TUD. MEASUREMENTS: Outcome was diagnosis (yes/no) of four T2DM complications (cerebrovascular accident, diabetic neuropathy, diabetic renal disease, myocardial infarction) and all-cause mortality. FINDINGS: Logistic regressions revealed that SUD was significantly associated with greater risk of cerebrovascular accident [TUD odds ratio (OR) = 1.79, OUD-OR = 1.94, cocaine use disorder OR = 2.67], diabetic neuropathy [TUD-adjusted OR (aOR) = 1.47, cocaine use disorder-aOR = 1.35, AUD-aOR = 1.27], diabetic renal disease (TUD-aOR = 1.25, OUD-OR = 1.34), myocardial infarction (TUD-OR = 1.96, OUD-OR = 2.01, cocaine use disorder-OR = 2.68, CUD-OR = 2.48, AUD-OR = 1.42) and mortality (TUD-OR = 1.15, cocaine use disorder-OR = 1.61, CUD-OR = 1.49, AUD-OR = 1.35). CONCLUSIONS: Among patients in Ohio USA with both type 2 diabetes mellitus (T2DM) and hypertension, those with substance use disorders appear to have greater risk for T2DM complications and all-cause mortality.
Authors: Roger Chou; Judith A Turner; Emily B Devine; Ryan N Hansen; Sean D Sullivan; Ian Blazina; Tracy Dana; Christina Bougatsos; Richard A Deyo Journal: Ann Intern Med Date: 2015-02-17 Impact factor: 25.391
Authors: Barbara A Yankey; Richard Rothenberg; Sheryl Strasser; Kim Ramsey-White; Ike S Okosun Journal: Eur J Prev Cardiol Date: 2017-08-08 Impact factor: 7.804
Authors: Juuso I Blomster; Sophia Zoungas; John Chalmers; Qiang Li; Clara K Chow; Mark Woodward; Giuseppe Mancia; Neil Poulter; Bryan Williams; Stephen Harrap; Bruce Neal; Anushka Patel; Graham S Hillis Journal: Diabetes Care Date: 2014-02-27 Impact factor: 19.112
Authors: Francesco Palmese; Maria Elena Bonavita; Giorgio Bedogni; Marco Domenicali; Enrico Pompili; Maria Teresa Migliano; Nicola Reggidori; Cecilia Di Stefano; Marta Grieco; Stefano Colazzo; Manuel Tufoni; Maurizio Baldassarre; Paolo Caraceni; Francesco Giuseppe Foschi; Fabrizio Giostra; Gabriele Farina; Rossella Del Toro Journal: Intern Emerg Med Date: 2022-10-05 Impact factor: 5.472
Authors: Kari A Stephens; Imara I West; Kevin A Hallgren; Brenda Mollis; Kris Ma; Dennis M Donovan; Brenda Stuvek; Laura-Mae Baldwin Journal: J Subst Abuse Treat Date: 2020-03
Authors: Sarah Forthal; Sugy Choi; Rajeev Yerneni; Zhongjie Zhang; David Siscovick; Natalia Egorova; Todor Mijanovich; Victoria Mayer; Charles Neighbors Journal: Med Care Date: 2021-10-01 Impact factor: 3.178